Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07473037

Efficacy of a Combined Oral and Topical Collagen Regimen Compared to Topical Collagen or Oral Collagen Regimens in Women With Skin Ageing Signs

This clinical study is conducted at one study site and in 165 women with visible signs of skin aging. It compares after 13 weeks the benefit of a combined oral collagen supplement and topical collagen serum regimen compared with oral collagen alone and topical collagen serum alone in reducing in women presenting visible signs of skin ageing .

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

45 year–60 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant having signed an Informed Consent Form (ICF) before any trial related activity is carried out;
  • Female participant;
  • Participant with a Fitzpatrick skin type I to III;
  • Participant aged 45 to 60 years inclusive at the time of signing the ICF;
  • Participant with a BMI ≥20 and < 29 kg/m²;
  • Participant presenting:
  • Cheek firmness score ≥3 and ≤6 on the 10-point scale;
  • Crow's feet wrinkle score ≥2 and ≤4 on the L'Oréal Atlas;
  • Global facial wrinkle score ≥3 and ≤6 on the 10-point scale.
  • Female participant of childbearing potential must use one of the reliable methods of contraception during the investigation and agree not to change it during the study;

A woman is considered of childbearing potential unless she is:

  • Postmenopausal for at least 12 months prior to screening visit;
  • Without uterus and/or both ovaries;
  • Has been surgically sterile for at least 6 months prior to Screening visit.
  • Participant must agree to use only the designated products
  • Participant willing and able to comply with all study procedures, lifestyle and dietary restrictions, and complete the entire study period
  • Participant affiliated to a health social security system (according to French Law).

Exclusion criteria

  • Participant who is pregnant or who is breast feeding;
  • Participant receiving hormone replacement therapy (HRT).
  • Participant who smokes more than two cigarettes per week;
  • Participant whose alcohol intake exceeds 2 drinks per week;
  • Participant with any uncontrolled diseases such as diabetes, hypertension, hyperthyroidism or hypothyroidism;
  • Presenting or having a history of eating disorder (e.g. anorexia, food allergy) or gastro-intestinal malabsorption such as celiac disease, Crohn's disease, lactose intolerance;
  • Participant with an history of sleeve or bypass;
  • Participant with skin abnormalities (e.g., scars, excessive hair, tattooing) or any dermatosis (e.g., psoriasis, eczema, acne vulgaris) on the face which could interfere with the study;
  • Participant with history of any severe disease or current condition which, in the opinion of the Investigator would put the participant at risk by participating in the study or would interfere significantly with the evaluation of study results
  • Participant with known or suspected hypersensitivity to any ingredient(s) of the investigational products;
  • Participants having undergone any aesthetic procedures (such as chemical peels, laser treatments, dermabrasions, injections, anti-ageing masks, hair implants, etc.) on the test areas within 6 months prior to the start of the study are excluded.
  • Participant who, in the opinion of the investigator, is unlikely to comply with the Clinical Study Protocol (e.g., alcoholism, drug dependency or psychotic state);
  • Participant having use systemic corticosteroids, immunosuppressive drugs, or retinoids (oral or topical) within 3 months prior to study enrollment;
  • Only for participants (20 in each group) who are willing to accept skin microbiopsies: The participant who has a contraindication to skin biopsies
  • Participant impossible to contact in case of emergency;
  • Participant with current participation in any other interventional clinical study, based on interview of the Participant;
  • Participant who is in an exclusion period in the National Biomedical Research Register of the French Ministry of Health at randomization;
  • Participant who has been deprived of their freedom by administrative or legal decision, or who is under care of a guardian or legal guardianship, or Participant hospitalized in a medical or social establishment for any reason.

Treatment and study plan

Oral collagen

Dietary Supplement

combination of oral collagen supplementation and topical application of collagen serum

topical application of collagen serum

Other

topical application of collagen serum

Primary outcomes

  1. Crow's feet score on the L'Oreal Skin Atlas (Caucasian type) scale ranging from 0=no wrinkles to 6=very deep severe wrinkles

    Time frame: Baseline, Week 3, Week 7, Week 13

Secondary outcomes

  1. Forhead wrinkle score on the L'Oreal Skin Atlas (Caucasian type) scale ranging from 0=no wrinkles to 5=very deep/severe wrinkles

    Time frame: baseline, week 3, week 7, week 13

  2. Glabellar's wrinkle score on the L'Oreal Skin Atlas (Caucasian type) scale ranging from 0=no wrinkles to 5=very deep/severe wrinkles

    Time frame: baseline, week 3, week 7, week 13

  3. Underneath eye wrinkle score on the L'Oreal Skin Atlas (Caucasian type) scale ranging from 0=no wrinkles to 5=very deep/severe wrinkles

    Time frame: baseline, week 3, week 7, week 13

  4. Nasolabial fold score on the L'Oreal Skin Atlas (Caucasian type) scale ranging from 0=no fold to 5=very deep/severe fold

    Time frame: baseline, week 3, week 7, week 13

  5. Upper lip wrinkle score on the L'Oreal Skin Atlas (Caucasian type) scale ranging from 0=no wrinkles to 6=very deep/severe wrinkles

    Time frame: baseline, week 3, week 7, week 13

  6. Wrinkles of the corner of the lip score on the L'Oreal Skin Atlas (Caucasian type) scale ranging from 0=no wrinkles to 6=very deep/severe wrinkles

    Time frame: baseline, week 3, week 7, week 13

  7. Ptosis of the lower part of the face on the L'Oreal Skin Atlas (Caucasian type) scale ranging from 0=no wrinkles to 5=very deep/severe fold

    Time frame: baseline, week 3, week 7, week 13

  8. Whole face wrinkles on a scale from 0=no visible wrinkle to 9= very visible wrinkle (clinical visual evaluation by the investigator)

    Time frame: baseline, week 3, week 7, week 13

  9. Skin firmness on a scale from 0=very firm skin to 9= very saggy/not firm skin (clinical tactile evaluation by the investigator)

    Time frame: baseline, week 3, week 7, week 13

  10. Skin elasticity on a scale from 0=very elastic skin to 9= very loose/not elastic skin (clinical tactile evaluation by the investigator)

    Time frame: baseline, week 3, week 7, week 13

  11. Skin tone eveness on a scale from 0=very even skin tone to 9= very even skin tone (clinical visual evaluation by the investigator)

    Time frame: baseline, week 3, week 7, week 13

  12. Skin radiance on a scale from 0=very radiant complexion to 9= uneven complexion/ dull complexion (clinical visual evaluation by the investigator)

    Time frame: baseline, week 3, week 7, week 13

  13. Skin smoothness on a scale from 0=very smooth skin texture, 9=very rough skin texture (clinical visual evaluation by the investigator)

    Time frame: baseline, week 3, week 7, week 13

  14. Skin density on a scale from0 = very low density, 9 = very high density (clinical tactile evaluation by the investigator)

    Time frame: baseline, week 3, week 7, week 13

  15. Assessment of the mechanical properties of the skin by measuring its elasticity, firmness, and viscoelasticity using a cutometer (units: penetration depth in mm/time)

    Time frame: baseline, week 3, week 7, week 13

    Cutometry is a widely used, non-invasive technique designed to assess the mechanical properties of the skin by measuring its elasticity, firmness, and viscoelasticity. The procedure involves applying a controlled suction force to the skin surface using a specialized probe, which lifts the skin into the device's aperture. The extent and rate at which the skin deforms under suction and then returns to its original state are recorded, providing quantitative data on skin biomechanics. Measurements will be taken on the randomized temple.

    In this study, the following key parameters will be selected for analysis:

    • R0: Total skin deformation, representing skin firmness (lower values indicate firmer skin).
    • R2: Gross elasticity, the ratio of elastic recovery to total deformation (reflects overall skin elasticity).
    • R5: Net elasticity, indicating the pure elastic portion of skin deformation, excluding viscous effects.
    • R7: Biological elasticity, measuring the ability of the skin to return
  16. Creating an imprint of a specific shape on the skin using a Dermotrac®. Its handle houses a spring-loaded piston that applies a consistent pressure of up to 2 kg on the skin.

    Time frame: baseline, week 3, week 7, week 13

    The Dermotrace® device (L'Oréal) is a small tool designed to create an imprint of a specific shape on the skin. Its handle houses a spring-loaded piston that applies a consistent pressure of up to 2 kg on the skin. The measuring head's marks are aligned along the axis of the thigh. During the procedure, a pressure of 1 kg is applied for 30 seconds. After this time, the head is removed, and the resulting imprint is evaluated using a reference scale provided by L'Oréal, ranging from 0 (no imprint) to 10 (a deep, clearly defined mark that accurately reflects the contours of the measuring head, including the outer circular border). The Dermotrace® score reflects the degree of skin deformation, which correlates with the mobility of fluids within the skin. The measurement should be taken on the face

  17. Dermis density using SIAscope (Spectophotometric intracutaneous analysis; arbitrary units)

    Time frame: baseline, week 3, week 7, week 13

    The SIAscope is a non-invasive imaging device used to assess skin pigmentation and sub-surface skin features by analyzing the absorption and scattering of light in the skin. It employs multispectral imaging technology, capturing images at different wavelengths to provide detailed information about melanin concentration, hemoglobin levels, and collagen structure beneath the skin surface. This allows for an objective evaluation of skin pigmentation disorders, sun damage, vascular conditions, and early signs of photoaging. Measurements will be taken on the randomized temple.

  18. Image acquisition: LC-OCT Acquisition

    Time frame: baseline, week 3, week 7, week 13

    Line-field Confocal Optical Coherence Tomography (LC-OCT) is a non-invasive 3D imaging technology that allows in vivo visualization of skin layers in their native state without preparation. The device enables switching between vertical (histology-like) and horizontal (confocal-like) modes and acquires volumetric 3D tissue stacks.

    This technique clearly images the stratum corneum, viable epidermis, dermis, and dermal-epidermal junction using live vertical, horizontal, and 3D modes.

    In this study, LC-OCT imaging will be performed on the forehead using the LC-OCT deepLive™ (DAMAE). The following parameters will be measured:

    • Stratum corneum thickness
    • Viable epidermis thickness
    • Dermal-epidermal junction undulation Three 3D stacks will be acquired per session to ensure reliable data.
  19. Image acquisition: Selfies acquisition

    Time frame: baseline, week 3, week 7, week 13

    Photographs (using both the back and front cameras) will be captured with an iPhone 15. Images taken with the back camera will be acquired by trained study personnel, while front camera images will be taken by the subjects themselves following brief instruction provided by the study staff. These photographs will be pseudonymized and stored securely in the sponsor's study files, ensuring that no personally identifiable information is included.

    13.3.3.3 ColorFace Acquisitions

  20. Image acquisition: ColorFace Acquisitions

    Time frame: Baseline, week 3, week 7, week 13

    Standardized photographs of the face (front and 45° left and right sides) will be taken using the ColorFace® (Newtone Technologies, Lyon, France). The ColorFace® has multiple lighting modes and can acquire up to 5 images in one setting from a user-definable shooting template without technician intervention.

    In this study, participants will be photographed using the following modalities:

    • Cross-polarized (polarizing filter angle: 90 degrees, no specular gloss on the skin surface and observation of color variations);
    • Standard 60 (polarizing filter angle: 60 degrees, observation of skin relief such as wrinkles);
    • Parallel-Polarized (polarizing filter angle: 0 degrees, observation of skin relief such as pores); All digital photographs will be named with the protocol number, the participant's SIN, the side of the body photographed, and the type of lighting used. These photographs will be pseudonymized and stored securely in the sponsor's study files, ensuring that no personally identi
  21. Subject Self-Assessment Questionnaire

    Time frame: week 3, week 7 and week 13

    At the Week 3, Week 7 and Week 13, the subjects will be questioned about the cosmetic acceptability of the study product using a 5-point scale (strongly agree, somewhat agree, neither agree nor disagree, somewhat disagree, strongly disagre) using a 20-questions questionnaire

  22. Global Investigator satisfaction on a scale from 0= not satisfied to 5= very satisfied with the clinical outcome

    Time frame: week 13

Other outcomes

  1. Microbiopsies (0.33 mm in diameter or the equivalent of a 23-gauge needle) for histology and gene expression of tissue rejuvenation at baseline and week 13

    Time frame: baseline, week 13

    according to Kislevitz M,, Lu KB, , Wamsley C, , Hoopman J, , Kenkel J et Akgul Y, Novel Use of Non-Invasive Devices and Microbiopsies to Assess Facial Skin Rejuvenation Following Laser Treatment. . Lasers Surg Med. 2020 Nov;52(9):822-830. doi: 10.1002/lsm.23233. Epub 2020 Mar.

Study contacts

Contact information is provided by the study sponsor or research team.

Claire Deloche-Bensmaine, phD

CONTACT

[email protected]

+33776112798

Julie Faure

CONTACT

[email protected]

+33776112798

Sponsors and collaborators

Lead sponsor

Vichy Laboratoires

Industry

Collaborators

  • CPCAD GIE
  • SKINPHARMA

Registry information

Official study title

Evaluation of the Efficacy of an in and Out Collagen Routine Versus the Serum Alone and Versus the Oral Supplement Alone in Women With Skin Ageing Signs

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Mar 16, 2026
Registry last updated
Mar 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.